Dextromethorphan and guaifenesin use needs to be monitored very carefully in sufferers with "very poor metabolizer" CYP2D6 enzyme amounts and individuals who will be sedated. This combination medication contains a significant median poisonous dose (TD50) to median successful dose (ED50) ratio (or therapeutic index) in these people. Delsym has an https://chemicalglobe.com/